Chronic Rhinosinusitis trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Chronic Rhinosinusitis. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month3 studies across 2 companies, in the next 180 days.
October 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| SNY | Sanofi | A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal PolypsNCT06834347Change from baseline in the endoscopic NPS | Phase 3 | Active, not recruiting | 2026-10-14 | in 55 d | 2026-05-20 |
November 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| SNY | Sanofi | A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal PolypsNCT06834360Change from baseline in the endoscopic NPS | Phase 3 | Active, not recruiting | 2026-11-06 | in 78 d | 2026-06-02 |
January 2027 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| AZN | AstraZeneca | A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With TezepelumabNCT06706817Change from baseline in nasal congestion | Phase 3 | Active, not recruiting | 2027-01-13 | in 146 d | 2026-08-05 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Chronic Rhinosinusitis
most recently updated first46 studies match.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AZN | AstraZeneca | — | A Study to Investigate the Clinical Outcome and Quality of Life in Chinese Post-operative CRSwNP PatientsNCT07446738observational• The observed and change from baseline of Sino-Nasal Outcome Test (SNOT)-22 score at week-52 | — | Recruiting | Procedure: Endoscopic Sinus Surgery (ESS) | Chronic Rhinosinusitis With Nasal Polyps | 200 | 2026-03-19 | 2027-10-21 | in 427 d | 2026-08-14 |
| AZN | AstraZeneca | — | A Study to Investigate NPS and Symptoms in Chinese Adult Participants With CRSwNP Initiating Treatment With TezepelumabNCT07520162To describe changes from baseline in nasal polyp score (NPS) | Phase 3 | Recruiting | Drug: Tezepelumab | Chronic Rhinosinusitis With Nasal Polyps | 230 | 2026-04-24 | 2028-03-01 | in 559 d | 2026-08-14 |
| AZN | AstraZeneca | — | ReAl-woRld Evaluation of tEzepelumab for Chronic rhinoSinusitis With Nasal Polyps in RussiaNCT07399665observational1. Change in endoscopic status of CRSwNP based on NPS | — | Recruiting | — | Chronic Rhinosinusitis With Nasal Polyps (CRSwNP), Asthma | 110 | 2025-12-25 | 2028-03-31 | in 589 d | 2026-08-13 |
| SNY | Sanofi | — | A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Adult Japanese Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal PolypsNCT07484230Change from baseline in the endoscopic NPS | Phase 3 | Withdrawnsponsor's stated reason: Sponsor decision. Not related to safety concern. | Drug: Itepekimab (SAR440340), Placebo | Chronic Rhinosinusitis With Nasal Polyps | 0 | 2026-05-08 | 2027-10-20 | in 426 d | 2026-08-13 |
| SNY | Sanofi | — | An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal PolypsNCT07424144Incidence of treatment-emergent adverse events (AEs), adverse events of special interest (AESIs), serious adverse events (SAEs), AEs leading to death, and AEs leading to permanent treatment discontinuation | Phase 3 | Active, not recruiting | Drug: Itepekimab (SAR440340), Placebo | Chronic Rhinosinusitis With Nasal Polyps | 59 | 2026-03-12 | 2027-02-17 | in 181 d | 2026-08-12 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)NCT06338995Mean Change From Baseline (CFBL) in Participant Reported Nasal Congestion Score (NCS) Severity | Phase 3 | Recruiting | Drug: LY3650150, Placebo, Standard therapy for INCS | Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | 510 | 2024-04-29 | May 2027 | ≤ 284 d | 2026-08-06 |
| AZN | AstraZeneca | — | A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With TezepelumabNCT06706817Change from baseline in nasal congestion | Phase 3 | Active, not recruiting | Combination product: Tezepelumab | Chronic Rhinosinusitis With Nasal Polyps | 181 | 2024-12-03 | 2027-01-13 | in 146 d | 2026-08-05 |
| SNY | Sanofi | — | Dupilumab in CRSsNPNCT04678856results2024-12-18Change From Baseline to Week 24 in Opacification of Sinuses Assessed by Computed Tomography (CT) Scan Using the Lund Mackay (LMK) Score in Dupilumab Group | Phase 2 | Completed | Drug: Dupilumab SAR231893, Placebo | Chronic Rhinosinusitis Without Nasal Polyps, Sinusitis, Chronic Sinusitis, Sinus Disorder, Respiratory Disorder | 71 | 2020-12-02 | 2023-11-14actual | — | 2026-07-30 |
| AZN | AstraZeneca | — | Prospective, Non-interventional Single-arm Study With Tezepelumab to Investigate the Change in Clinical and Patient-reported Outcomes in Patients With CRSwNP in Real-world (PETRICHOR)NCT07633158observationalMean change from baseline in sino-nasal symptoms measured by SNOT-22 total score at clinical routine visits. | — | Recruiting | — | Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | 200 | 2026-06-10 | 2029-12-31 | in 1,229 d | 2026-07-29 |
| REGN | Regeneron Pharmaceuticals | $76.1B | Study Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)NCT04959448observationalBaseline Patient Characteristics | — | Active, not recruiting | Drug: DUPIXENT® | Chronic Rhinosinusitis With Nasal Polyposis | 717 | 2021-08-12 | 2027-03-25 | in 217 d | 2026-07-13 |
| SNY | Sanofi | — | Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical StudyNCT06914908Incidence of participants with treatment-emergent adverse events (TEAEs) including adverse events of special interest (AESI), and serious adverse events (SAEs) | Phase 2 | Enrolling by invitation | Drug: Lunsekimig, Mometasone furoate nasal spray (MFNS) | Chronic Rhinosinusitis With Nasal Polyps | 71 | 2025-05-12 | 2031-01-29 | in 1,623 d | 2026-07-02 |
| SNY | Sanofi | — | Study in Adults With Severe Chronic Rhinosinusitis With Nasal Polyposis Treated With Dupilumab in FranceNCT06393946observationalPatient characteristics: Age | — | Active, not recruiting | Drug: Dupilumab | Chronic Rhinosinusitis With Nasal Polyposis | 150 | 2023-10-20 | 2026-07-31 | — | 2026-06-04 |
| SNY | Sanofi | — | A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal PolypsNCT06834360Change from baseline in the endoscopic NPS | Phase 3 | Active, not recruiting | Drug: Itepekimab (SAR440340), Placebo, Mometasone furoate nasal spray (MFNS) | Chronic Rhinosinusitis With Nasal Polyps | 216 | 2025-02-06 | 2026-11-06 | in 78 d | 2026-06-02 |
| SNY | Sanofi | — | A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal PolypsNCT06834347Change from baseline in the endoscopic NPS | Phase 3 | Active, not recruiting | Drug: Itepekimab (SAR440340), Placebo, Mometasone furoate nasal spray (MFNS) | Chronic Rhinosinusitis With Nasal Polyps | 231 | 2025-02-12 | 2026-10-14 | in 55 d | 2026-05-20 |
| SNY | Sanofi | — | A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti--IL-33 mAb) in Participants With Chronic Rhinosinusitis Without Nasal PolypsNCT06691113Change from baseline in sinus (maxillary, ethmoid) percent opacification volume assessed by CT scan | Phase 2 | Active, not recruiting | Drug: Itepekimab (SAR440340), Placebo, Mometasone furoate nasal spray (MFNS) | Chronic Rhinosinusitis Without Nasal Polyps | 66 | 2024-12-16 | 2026-03-31actual | — | 2026-05-05 |
| SNY | Sanofi | — | A Proof-of-concept Study of Lunsekimig Compared With Placebo in Adults With Chronic Rhinosinusitis With Nasal PolypsNCT06454240Change in bilateral endoscopic nasal polyp score (NPS). | Phase 2 | Completed | Drug: lunsekimig, placebo | Chronic Rhinosinusitis With Nasal Polyps | 79 | 2024-07-17 | 2026-01-29actual | — | 2026-04-28 |
| MDT | Medtronic | $117.9B | Propel Drug-Eluting Sinus Implant Family IBUKI CohortNCT07546682observationalSNOT-22 total score change | — | Recruiting | Other: None, observational standard of care study | Chronic Rhinosinusitis (CRS) | 100 | Apr 2026 | May 2027 | ≤ 284 d | 2026-04-23 |
| AZN | AstraZeneca | — | Efficacy and Safety Study of Benralizumab in Patient With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (ORCHID)NCT04157335results2026-02-19Change From Baseline in Endoscopic Total Nasal Polyp Score (NPS) at Week 56 | Phase 3 | Terminatedsponsor's stated reason: The study has a double-blind period and an open-label period. The study did not meet its primary endpoints after the primary LSLV and the decision was taken to terminate the study early. | Biological: Benralizumab 30 mg, Matched placebo | Nasal Polyposis, Eosinophilic Chronic Rhinosinusitis | 295 | 2019-11-25 | 2024-08-06actual | — | 2026-02-19 |
| LYRA | Lyra Therapeutics | $425,972 | Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis in Adults (ENLIGHTEN 2)NCT05295459results2026-02-19Change From Baseline (CFBL) in the 7-day Average Composite Score of 3 Cardinal Symptoms (3CS) in Participants Without Nasal Polyps | Phase 3 | Completed | Drug: LYR-210, Sham procedure control · Other: Background therapy | Chronic Sinusitis, Chronic Rhinosinusitis (Diagnosis) | 182 | 2022-05-13 | 2025-04-02actual | — | 2026-02-19 |
| AZN | AstraZeneca | — | Efficacy and Safety of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal PolyposisNCT04851964results2026-01-27Change From Baseline in Total Nasal Polyp Score at Week 52 | Phase 3 | Completed | Biological: Experimental: Tezepelumab · Other: Placebo · Drug: Mometasone furoate or equivalent intranasal corticosteroid | Chronic Rhinosinusitis With Nasal Polyps | 416 | 2021-04-22 | 2024-09-23actual | — | 2026-01-27 |
| MDT | Medtronic | $117.9B | Propel Drug-Eluting Sinus Stent Family Open CohortNCT05925985observationalLong-term safety and efficacy of corticosteroid-eluting implants in patients with CRS undergoing Functional Endoscopic Sinus Surgery (FESS) | — | Completed | Other: NA-Observational Registry | Chronic Rhinosinusitis (Diagnosis) | 215 | 2023-06-01 | 2025-02-19actual | — | 2026-01-20 |
| INSM | Insmed Incorporated | $28.1B | A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)NCT06013241Change From Baseline to the 28-day Average of Daily Sinus Total Symptom Score (sTSS) at Week 24 | Phase 2 | Completed | Drug: Brensocatib, Placebo, Mometasone furoate nasal spray (MFNS) | Chronic Rhinosinusitis Without Nasal Polyps | 288 | 2023-10-30 | 2025-09-30actual | — | 2025-11-10 |
| SNY | Sanofi | — | EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 PatientsNCT04998604results2025-10-23Change From Baseline to Week 24 in Nasal Polyp Score | Phase 4 | Completed | Drug: Dupilumab, Omalizumab, Placebo | Chronic Rhinosinusitis With Nasal Polyps, Asthma | 360 | 2021-09-27 | 2024-10-16actual | — | 2025-10-23 |
| SNY | Sanofi | — | Dupilumab in Chinese Adult Participants With CRSwNPNCT05878093results2025-09-25Change From Baseline in Nasal Polyps Score at Week 24 | Phase 3 | Completed | Drug: Dupilumab, Placebo, Budesonide | Chronic Rhinosinusitis With Nasal Polyps | 63 | 2023-05-16 | 2024-09-06actual | — | 2025-09-25 |
| SNY | Sanofi | — | Dupilumab in Japanese Patients With Chronic Rhinosinusitis With Nasal Polyp (SINUS-M52)NCT05049122results2024-01-22Percentage of Participants With NPS Improvement From Baseline >=1 at Week 24 | Phase 4 | Completed | Drug: Dupilumab SAR231893 | Chronic Rhinosinusitis With Nasal Polyps | 25 | 2021-10-22 | 2022-12-21actual | — | 2025-09-11 |
| UPB | Upstream Bio Inc. | $375M | A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Participants With Chronic Rhinosinusitis With Nasal PolypsNCT06164704Change From Baseline in Nasal Polyp Score (NPS) at Week 24 | Phase 2 | Completed | Drug: Verekitug (UPB-101), Placebo | Chronic Rhinosinusitis With Nasal Polyps | 81 | 2023-12-18 | 2025-07-07actual | — | 2025-08-15 |
| MDT | Medtronic | $117.9B | Product Surveillance Registry; Ear, Nose and Throat - EXTEND CohortNCT06671561observationalTo characterize the SNOT-22 total score change from baseline to Month 6 in patients with CRS undergoing FESS | — | Withdrawnsponsor's stated reason: New study design and data collection needed | Device: Observational data collection from patients with chronic rhinosinusitis (CRS) receiving PROPEL sinus implant(s) following functional endoscopic sinus surgery (FESS) | Chronic Rhinosinusitis (CRS) | 0 | 2025-01-30 | Aug 2026 | ≤ 11 d | 2025-05-15 |
| LYRA | Lyra Therapeutics | $425,972 | Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis in AdultsNCT05219968results2025-05-02Change From Baseline (CFBL) in the 7-day Average Composite Score of 3 Cardinal Symptoms (3CS) in Participants Without Nasal Polyps. | Phase 3 | Completed | Drug: LYR-210, Sham procedure control · Other: Background Therapy | Chronic Sinusitis, Chronic Rhinosinusitis (Diagnosis) | 196 | 2022-01-27 | 2024-03-04actual | — | 2025-05-02 |
| LYRA | Lyra Therapeutics | $425,972 | LYR-220 for Adult Subjects With Chronic Rhinosinusitis (BEACON Study)NCT05035654results2024-12-17Product-related Unexpected Serious Adverse Events | Phase 2 | Completed | Drug: LYR-220 Design 1 (Part 1 only), LYR-220 Design 2 (Part 1 and Part 2), Bilateral sham procedure control (Part 2) | Chronic Sinusitis, Chronic Rhinosinusitis (Diagnosis) | 48 | 2021-11-23 | 2023-08-30actual | — | 2024-12-17 |
| OGN | Organon and Co | $3.6B | Mometasone Furoate Nasal Spray for Treatment of Nasal Polyposis After Surgery (Study P03218)NCT00731185Time to relapse in polyp score after surgery | Phase 3 | Completed | Drug: Mometasone Furoate Nasal Spray, Placebo | Nasal Polyps | 162 | 2003-09-01 | 2005-09-01actual | — | 2024-08-15 |
| IART | Integra LifeSciences Corporation | $1.4B | Global Sinus Surgery RegistryNCT02347943results2019-02-27observationalNumber of Participants Completing Follow-Up Visits | — | Terminated | — | Chronic Rhinosinusitis, Recurrent Acute Rhinosinusitis | 252 | 2015-01-01 | 2015-11-01actual | — | 2024-07-12 |
| IART | Integra LifeSciences Corporation | $1.4B | Canadian Health Economics, Outcome, and Effectiveness Comparison of Treatment in Patients With Chronic RhinosinusitisNCT01455948The direct and indirect costs of treatment of frontal and other sinus disease with Functional Endoscopic Sinus Surgery or balloon sinuplasty. | Not applicable | Terminated | Device: Relieva Balloon Sinuplasty™ System · Procedure: Functional Endoscopic Sinus Surgery | Chronic Rhinosinusitis | 25 | Feb 2012 | Nov 2012actual | — | 2024-07-11 |
| SNY | Sanofi | — | A Study in Male and Female Adult Participants With Chronic Rhinosinusitis With Nasal Polyps In the Greater Gulf RegionNCT05649813observationalPercentage of participants with mild, moderate or severe disease (measured by visual analogue scale [VAS] score) | — | Completed | — | Chronic Rhinosinusitis With Nasal Polyps | 148 | 2022-11-20 | 2024-06-14actual | — | 2024-07-11 |
| OGN | Organon and Co | $3.6B | A Study of the Effectiveness and Safety of Mometasone Furoate Nasal Spray (MFNS, SCH 032088) for the Treatment of Nasal Polyps (P05604)NCT01386125results2013-12-19Change From Baseline in Congestion/Obstruction Score | Phase 3 | Completed | Drug: Mometasone Furoate Nasal Spray (MFNS), Placebo for MFNS | Nasal Polyps | 748 | Jun 2011 | Feb 2013actual | — | 2024-05-21 |
| OGN | Organon and Co | $3.6B | Study of Nasonex® for the Treatment of Nasal Polyps in Pediatric Subjects Between Ages of 6 and Less Than 18 Years Old (P04292)NCT00378378results2010-07-20Change From Baseline 24-hour Urinary Free Cortisol Level | Phase 3 | Completed | Drug: Mometasone Furoate Nasal Spray (MFNS), Placebo nasal spray | Nasal Polyps | 127 | Jul 2006 | Jun 2008actual | — | 2024-05-20 |
| LYRA | Lyra Therapeutics | $425,972 | LYR-210 Depot (LYR-210) for Adult Subjects With Chronic Sinusitis (LANTERN Study)NCT04041609results2023-06-06Change From Baseline (CFBL) in Chronic Sinusitis Symptom Scores at Week 4 | Phase 2 | Completed | Drug: LYR-210 · Other: Sham comparator | Chronic Sinusitis, Chronic Rhinosinusitis (Diagnosis) | 71 | 2019-05-09 | 2020-03-25actual | — | 2023-07-25 |
| AZN | AstraZeneca | — | RANS. Study in Patients With Severe Eosinophilic Asthma and Nasal Polyps.NCT05180357observationalBaseline demographics, clinical characteristics, and background treatments, as well as PROs for asthma control and HRQoL, asthma exacerbation, and healthcare resource utilization. | — | Completed | Other: FASENRA(benralizumab) | Severe Eosinophilic Asthma, Nasal Polyps | 273 | 2021-11-23 | 2022-10-28actual | — | 2023-04-19 |
| PFE | Pfizer | $155.3B | Study Of PF-06817024 In Healthy Subjects, In Patients With Chronic Rhinosinusitis With Nasal Polyps And in Patients With Atopic DermatitisNCT02743871results2022-05-19Number of Participants With All-causality Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) in Part 1 | Phase 1 | Completed | Biological: PF-06817024, PF-06817024, PF-06817024, PF-06817024, PF-06817024 · Other: Placebo for PF-06817024, Placebo for PF-06817024, Placebo for PF-06817024, Placebo for PF-06817024, Placebo for PF-06817024 | Healthy, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis | 97 | 2016-04-27 | 2021-03-09actual | — | 2022-05-19 |
| ANAB | AnaptysBio, Inc. | $1.7B | Etokimab in Adults With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)NCT03614923results2022-01-24Change From Baseline in Nasal Polyp Score (NPS) to Week 16 | Phase 2 | Completed | Biological: Etokimab, Placebo · Drug: Mometasone Furoate Nasal Spray | Chronic Rhinosinusitis | 105 | 2018-11-29 | 2020-09-02actual | — | 2022-01-24 |
| AZN | AstraZeneca | — | Efficacy and Safety Study of Benralizumab for Patients With Severe Nasal PolyposisNCT03401229results2021-10-12Change From Baseline in Total NPS at Week 40 | Phase 3 | Completed | Biological: Benralizumab 30 mg SC + Mometasone Furoate, Matching placebo SC + Mometasone Furoate | Nasal Polyposis | 413 | 2018-01-15 | 2020-07-31actual | — | 2021-10-12 |
| GOSS | GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc. | $70M | GB001 in Adult Participants With Chronic RhinosinusitisNCT03956862results2021-07-30Change From Baseline to Week 16 in Sino-Nasal Outcome Test (SNOT) 22 Total Score | Phase 2 | Completed | Drug: GB001, Placebo | Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP), Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | 97 | 2019-05-16 | 2020-07-09actual | — | 2021-08-23 |
| SNY | Sanofi | — | Controlled Clinical Study of Dupilumab in Patients With Nasal PolypsNCT02898454results2019-10-23Change From Baseline at Week 24 in Nasal Congestion/Obstruction Symptom Severity Score | Phase 3 | Completed | Drug: Dupilumab SAR231893 (REGN668), Placebo, Mometasone furoate nasal spray | Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP) | 448 | 2016-11-28 | 2018-08-27actual | — | 2019-10-23 |
| SNY | Sanofi | — | A Controlled Clinical Study of Dupilumab in Patients With Bilateral Nasal PolypsNCT02912468results2019-07-25Change From Baseline at Week 24 in Nasal Congestion/Obstruction Symptom Severity Score | Phase 3 | Completed | Drug: Dupilumab SAR231893 (REGN668), Placebo, Mometasone furoate 50 micrograms | Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP) | 276 | 2016-12-05 | 2018-07-05actual | — | 2019-07-25 |
| 4151.T | Kyowa Kirin Co., Ltd. | $8.4B | Study of Benralizumab (KHK4563) in Patients With Eosinophilic Chronic RhinosinusitisNCT02772419The change from baseline in nasal polyp score at Week 12 | Phase 2 | Completed | Drug: benralizumab, benralizumab, Placebo | Eosinophilic Chronic Rhinosinusitis | 63 | Jun 2016 | 2017-03-27actual | — | 2018-04-23 |
| SNY | Sanofi | — | An Evaluation of Dupilumab in Patients With Nasal Polyposis And Chronic Symptoms Of SinusitisNCT01920893results2017-06-02Change From Baseline in Bilateral Endoscopic Nasal Polyp Score (NPS) at Week 16 | Phase 2 | Completed | Drug: Placebo (for dupilumab), Dupilumab, Mometasone furoate nasal spray | Nasal Polyps | 60 | Aug 2013 | Nov 2014actual | — | 2017-06-26 |
| AMGN | Amgen | $229.9B | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 282 in Healthy Subjects and Subjects With Chronic Rhinosinusitis With Nasal PolypsNCT02170337Safety and tolerability | Phase 1 | Completed | Drug: AMG 282, Placebo | Chronic Rhinosinusitis With Nasal Polyps | 41 | Jul 2014 | May 2016actual | — | 2016-06-01 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Chronic Rhinosinusitis is matched — 11 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Chronic Rhinosinusitis With Nasal Polyps
- Chronic Rhinosinusitis (Diagnosis)
- Nasal Polyps
- Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
- Chronic Rhinosinusitis
- Chronic Rhinosinusitis Without Nasal Polyps
- Chronic Rhinosinusitis (CRS)
- Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)
- Chronic Rhinosinusitis With Nasal Polyposis
- Eosinophilic Chronic Rhinosinusitis
- Nasal Polyposis
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Chronic Rhinosinusitis” (a text search, wider than this page)